ORIC appoints Ashraf Hanna as CEO
Prior to joining ORIC, Dr. Hanna was Vice President of Commercial and Medical Affairs Finance at Genentech and CFO of the Genentech Foundation.
He was a member of Genentech’s Commercial Leadership Committee, and previously headed Genentech’s Alliance Management and Portfolio Planning groups.
Before Genentech, he was at Tanox and McKinsey and Company.
Dr. Hanna holds a PhD in Physics from Harvard University, an MD from the University of Massachusetts, and undergraduate degree in Physics from the University of Chicago.
Dr. Hanna will take over from Rich Heyman, PhD, who has been the interim CEO for the past six months. Dr. Heyman will remain on ORIC’s Board of Directors.
Prior to joining ORIC, Dr. Mootz was Vice President of Corporate Development at Achaogen, where she led corporate development & alliance management, served as the project team leader for the company’s lead asset, and contributed to successful financings, including an IPO.
Before Achaogen, she held a variety of roles across corporate development, marketing, and strategic planning at BiPar Sciences, Genentech, and L.E.K. Consulting.
Dr. Mootz holds a PhD in biochemistry from Harvard University and a BS in biology from Duke University. ■
LATEST MOVES FROM California
- ChromaDex appoints Steven Rubin to board
- Impax Laboratories appoints Paul M. Bisaro as CEO
- Retrophin names John A. Orwin to board
- Intel appoints two to board
- Walt Disney Company extends CEO's contract to 2019
More inside POST